Seelos Therapeutics, Inc. (SEELQ) - Net Assets
Based on the latest financial reports, Seelos Therapeutics, Inc. (SEELQ) has net assets worth $-28.13 Million USD as of June 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.38 Million) and total liabilities ($30.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read SEELQ current and long-term liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-28.13 Million |
| % of Total Assets | -1181.56% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1123.62 |
Seelos Therapeutics, Inc. - Net Assets Trend (2020–2023)
This chart illustrates how Seelos Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Seelos Therapeutics, Inc. for the complete picture of this company's asset base.
Annual Net Assets for Seelos Therapeutics, Inc. (2020–2023)
The table below shows the annual net assets of Seelos Therapeutics, Inc. from 2020 to 2023. For live valuation and market cap data, see Seelos Therapeutics, Inc. (SEELQ) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-33.51 Million | -215.80% |
| 2022-12-31 | $-10.61 Million | -118.51% |
| 2021-12-31 | $57.32 Million | +2128.73% |
| 2020-12-31 | $2.57 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Seelos Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17746400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $219.12 Million | % |
| Total Equity | $-33.51 Million | 100.00% |
Seelos Therapeutics, Inc. Competitors by Market Cap
The table below lists competitors of Seelos Therapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WM Technology Inc
NASDAQ:MAPSW
|
$65.35 |
|
Jack Nathan Medical Corp
V:JNH
|
$67.14 |
|
Seneca Growth Capital VCT PLC
LSE:HYG
|
$69.12 |
|
Innoviz Technologies Ltd
NASDAQ:INVZW
|
$70.41 |
|
RPCG PCL F
F:R4Q
|
$56.92 |
|
Godha Cabcon & Insulation Limited
NSE:GODHA
|
$56.06 |
|
Future Enterprises Limited
NSE:FEL
|
$49.18 |
|
Prairie Lithium Limited
AU:PL9
|
$48.63 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Seelos Therapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -10,611,000 to -33,510,000, a change of -22,899,000.
- Net loss of 37,882,000 reduced equity.
- Share repurchases of 1,195,000 reduced equity.
- New share issuances of 20,114,000 increased equity.
- Other factors decreased equity by 3,936,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-37.88 Million | -113.05% |
| Share Repurchases | $1.20 Million | -3.57% |
| Share Issuances | $20.11 Million | +60.02% |
| Other Changes | $-3.94 Million | -11.75% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Seelos Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $181.10 | $0.00 | x |
| 2021-12-31 | $2086.45 | $0.00 | x |
| 2022-12-31 | $-380.21 | $0.00 | x |
| 2023-12-31 | $-27.37 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Seelos Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-214.47%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -742.65% | 0.00% | 0.00x | 6.80x | $-19.36 Million |
| 2021 | -115.22% | 0.00% | 0.00x | 1.46x | $-71.78 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-72.47 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-34.53 Million |
Industry Comparison
This section compares Seelos Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Seelos Therapeutics, Inc. (SEELQ) | $-28.13 Million | -742.65% | N/A | $58.00 |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therap… Read more